How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-obstructive-lung-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chronic obstructive lung disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic obstructive lung disease (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic obstructive lung disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Yupelri	REVEFENACIN	Mylan Ireland Ltd	Anticholinergic [EPC]	Muscarinic acetylcholine receptor M3	2018-01-01
Striverdi Respimat	OLODATEROL	Boehringer Ingelheim	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2014-01-01
Incruse Ellipta	UMECLIDINIUM	Glaxo Grp England	Anticholinergic	Muscarinic acetylcholine receptor M4	2013-01-01
Breo Ellipta	VILANTEROL	Glaxo Grp Ltd	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2013-01-01
Tudorza Pressair	ACLIDINIUM BROMIDE	Covis	Anticholinergic	M3 receptors, beta 2 -adrenergic receptors	2012-01-01
Arnuity Ellipta	FLUTICASONE FUROATE	Haleon Us Holdings	Corticosteroid	Glucocorticoid receptor	2007-01-01
Brovana	ARFORMOTEROL	Lupin	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2006-01-01
Cuvposa	GLYCOPYRRONIUM BROMIDE	Shionogi	Anticholinergic	Muscarinic acetylcholine receptor M1	1961-01-01
Incruse	Incruse	Fundacio Privada Mon Clinic Barcelona		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
Brovana	Brovana	Wake Forest University Health Sciences		Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-3 adrenergic receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Chronic obstructive lung disease
Glaxo Grp England · 2 drugs in Chronic obstructive lung disease
Covis · 1 drug in Chronic obstructive lung disease
Fundacio Privada Mon Clinic Barcelona · 1 drug in Chronic obstructive lung disease
Glaxo Grp Ltd · 1 drug in Chronic obstructive lung disease
Haleon Us Holdings · 1 drug in Chronic obstructive lung disease
Lupin · 1 drug in Chronic obstructive lung disease
Mylan Ireland Ltd · 1 drug in Chronic obstructive lung disease
Proveca Pharma Limited · 1 drug in Chronic obstructive lung disease
Shionogi · 1 drug in Chronic obstructive lung disease
Wake Forest University Health Sciences · 1 drug in Chronic obstructive lung disease
Yonsei University · 1 drug in Chronic obstructive lung disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic obstructive lung disease:

Cite this brief

Drug Landscape (2026). Chronic obstructive lung disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-obstructive-lung-disease. Accessed 2026-06-10.

Chronic obstructive lung disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing